Biocontainment Research Support Services Core

生物防护研究支持服务核心

• 批准号: 10793910
• 负责人: Karen Marie Dobos
• 金额: $ 77.88万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-18 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10793910
• 关键词: Acute; Animal Model; Animals; Biocompatible Materials; Biological; Biological Assay; Bioreactors; Cells; Centers of Research Excellence; Characteristics; Chemicals; Clinical Research; Clinical Trials; Collection; Colorado; Cryoultramicrotomy; Cyclic GMP; Databases; Development; Diagnostic; Dissection; Domestic Animals; Emerging Communicable Diseases; Equipment and supply inventories; Fresh Tissue; Growth; Health system; Histology; Human; Immunity; In Vitro; Infection; Infrastructure; Investments; Laboratories; Laboratory Animals; Mass Spectrum Analysis; Microbial Physiology; Modeling; Outcome; Pathogenesis; Pathology; Preparation; Process; Production; Proteomics; Qualifying; Reagent; Recording of previous events; Reproducibility; Research; Research Personnel; Research Support; Resource Development; Resources; Sampling; Series; Services; Study models; System; Technology; Testing; Universities; Vaccines; Viral; Workforce Development; biodefense; biosafety level 3 facility; cGMP production; cell bank; design; emerging pathogen; expectation; forging; health economics; improved; in vivo; innovation; laser capture microdissection; manufacturing scale-up; mass spectrometric imaging; metabolomics; molecular mass; multidisciplinary; new technology; pandemic pathogen; pandemic potential; pathogen; pathogenic bacteria; pathogenic virus; pre-clinical; preclinical study; preservation; programs; response; scale up; screening; socioeconomics; spillover event; synergism; tool; transcriptomics; transmission process; vaccine trial; vaccinology

Project Summary: RMRBL UC7 Core 3 The Rocky Mountain Regional Biocontainment Laboratory (RMRBL) was conceived concomitant with a Research Center for Excellence in Biodefense / Emerging Infectious Diseases. The outcome of these synergized investments in infrastructure and research was a multidisciplinary team of investigators and core research services. The RMRBL’s ability to respond to emerging and persistent pathogen threats are due to our collective understanding of pathogen characteristics, pathogenesis of infection, immunity and host range. Our prolific history of rapid response to high consequence pathogens posing a threat to public and socioeconomic health is due not only to the diverse strengths of the resident investigator teams, but also our ability to conduct these important studies in BSL3 facilities. Specifically, the CSU RMRBL has strengths in defining and optimizing in vitro culture conditions for pathogens and pathogen inactivation, establishing the requisite animal models to investigate wildlife and domestic animal spillover events and reservoir potential, and vaccine models using both viable and inactivated infectious materials produced in vitro. Further, the CSU RMRBL has expertise in cutting-edge technologies to study microbial physiology and animal models; such as conducting proteomic and metabolomics mass spectrometry analyses, detailed histopathologic analyses using spatial transcriptomics and AI-driven quantitative pathology scoring. Lastly, our collective research teams have established programs for supplying biological reagents that can be robustly used for animal and human clinical research, including inactivated biomaterials that can be safely and reproducibly used outside the BSL3. In this Core, we culminate our collective strengths into one Biocontainment Research Resources Core within the BSL3 facilities of the RMRBL. This resultant pathogen characterization core devises our capacity through independent and highly interactive aims; Aim 1: Natural reservoirs of infection and spillover threat for pathogens of pandemic potential; Aim 2: Reagents and models for vaccine and diagnostics studies for pathogens of pandemic potential; and Aim 3: Pathogen:Host materials processing for molecular mass spectrometry imaging and single cell ‘omics analyses. The RMRBL BSL3 Pathogen Characterization core provides opportunities to synergize activities, expand our resources across the RBL network and to additional partners, forge new technologies within the RMRBL BSL3, and ultimately improve our ability to adapt and rapidly deliver research resources acutely responsive to pathogens possessing a threat to our health systems.

项目摘要：RMRBLUC7 Core 3 落基山区域生物遏制实验室(RMRBL)是伴随而来的 拥有卓越的生物防御/新发传染病研究中心。这个 在基础设施和研究方面的这些协同投资的结果是一个多学科的 调查团队和核心研究服务。RMRBL应对新出现的问题的能力 而持续的病原体威胁是由于我们对病原体的集体理解 感染的特点、发病机制、免疫力和寄主范围。我们多产的快速历史 对对公众和社会经济健康构成威胁的高后果病原体的反应是 不仅是因为驻地调查员团队的不同优势，而且是因为我们有能力 在BSL3设施中进行这些重要研究。具体来说，CSU RMRBL在以下方面具有优势 确定和优化病原菌和病原菌灭活的体外培养条件， 建立必要的动物模型来研究野生动物和家养动物的溢出效应 事件和存储潜力，以及使用活的和灭活的传染病的疫苗模型 在体外生产的材料。此外，CSU RMRBL在尖端技术方面拥有专业知识 研究微生物生理学和动物模型；例如进行蛋白质组学和 代谢组质谱分析，详细的组织病理学分析使用空间 转录学和人工智能驱动的定量病理评分。最后，我们的集体研究团队 已经建立了计划，以提供可以有力地用于动物的生物试剂 和人类临床研究，包括可以安全和 在BSL3外可重复使用。在这个核心中，我们将我们的集体力量融为一体 生物遏制研究资源中心BSL3设施内的核心资源。由此产生的结果 病原体鉴定核心通过独立和高度互动来设计我们的能力 目标1：大流行病原体的自然感染源和溢出威胁 潜力；目标2：疫苗和病原体诊断研究的试剂和模型 大流行的可能性；和目标3：病原体：处理分子质量的宿主材料 光谱成像和单细胞组学分析。 RMRBLBSL3病原体特性核心提供了协同活动的机会， 将我们的资源扩展到整个RBL网络，并提供给其他合作伙伴，打造新技术 在RMRBL BSL3中，并最终提高我们适应和快速交付研究的能力 对对我们的卫生系统构成威胁的病原体做出敏锐反应的资源。